301.08 0.00 (0.00%)
After hours: 5:18PM EST
|Bid||293.60 x 100|
|Ask||301.07 x 900|
|Day's Range||292.23 - 308.75|
|52 Week Range||207.51 - 372.61|
|Beta (3Y Monthly)||2.04|
|PE Ratio (TTM)||65.17|
|Earnings Date||Jan 28, 2019 - Feb 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||359.75|
Medtronic (MDT) demonstrated improved performances at CER on growth in all business segments. However, costs continue to escalate.
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
Illumina, Inc. today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
Medical technology stocks hit record highs in 2018 and three of the fastest-growing stocks among them have tacked on double-digit earnings growth for the past five years.
The company already had a dominant position in the fast-growing gene sequencing market before strengthening its position with the acquisition of Pacific Biosciences
The future of genetic medicine — and DNA stocks — is extremely bullish over the long term. But as is normal of any emerging technology, there will be plenty of bumps along the road. The good news is that those bumps will provide many opportunities to buy DNA stocks along the way.
Earlier in the month, Illumina (ILMN) made an aggressive and surprising move: acquiring Pacific Biosciences (PACB), one of its direct competitors, for $1.2 billion. To date, this is the largest acquisition that Illumina has ever made. Warning! GuruFocus has detected 1 Warning Sign with ILMN.
Nine companies have majority ‘buy’ ratings, with upside potential of as much as 123%, according to analysts.
The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp
Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.